WO2005077189A1 - Method of treatment - Google Patents

Method of treatment Download PDF

Info

Publication number
WO2005077189A1
WO2005077189A1 PCT/US2005/002775 US2005002775W WO2005077189A1 WO 2005077189 A1 WO2005077189 A1 WO 2005077189A1 US 2005002775 W US2005002775 W US 2005002775W WO 2005077189 A1 WO2005077189 A1 WO 2005077189A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight
composition
chloride
magnesium
nasal
Prior art date
Application number
PCT/US2005/002775
Other languages
French (fr)
Inventor
Scott Cordray
Original Assignee
Scott Cordray
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scott Cordray filed Critical Scott Cordray
Publication of WO2005077189A1 publication Critical patent/WO2005077189A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera

Definitions

  • the present invention relates to the treatment of irritations and inflammations of the nasal passageways and cavity. More particularly, there is provided an aqueous composition of inorganic salts that prevents the degranulation of mast cells, inhibits the release of arachadonic acid and 5-lipoxygenase enzyme and irrigates the nasal passageways.
  • Allergic rhinitis, sinusitis, and epistaxis, as well as common irritations, can each be induced by any one of smoke, chemicals, pollens, mold or dust mites. Pollens cause the release of serine proteases such as tryptase and chymase and the activation of IgE which causes the degranulation of mast cells so as to initiate the acute inflammatory cycle.
  • PARS proteinase activating factors
  • PAR-2 proteinase activating factors
  • Cromolyn inhibits the activation of PAR-2 and aids in the prevention of the degranulation of mast cells. Since any different number of factors are involved in causing nasal irritations and inflammations, it would be preferable to have a method of treatment which can reduce the allergens or irritants in the nasal passageways that can be used over long periods of time as well as treat any inflammations that can be used by children as well as adults.
  • an aqueous composition and method for treating the symptoms associated with the irritation and inflammation of nasal passages and nasal cavity caused by allergens and irritants which cause the degranulation of mast cells, release of arachadonic acid and serine proteases More particular, there is provided a method of irrigating and treating the nasal passageways with an aqueous composition comprising a) About 1 to 10 percent by weight of salts comprising 1) About 45 to 60% of magnesium chloride, 2) About 29 to 41% of potassium chloride, and 3) About 1 to 4% of sodium chloride. b) The remainder being water.
  • the composition is buffered by a pH of about 6.0 to 7.5.
  • the composition may include plant extracts especially for irrigation and as a decongestant.
  • the composition contains about 1 to 5% by weight of salts selected from the group consisting of magnesium bromide, calcium chloride, calcium bromide, sodium bromide and magnesium sulfate (Epsom salts).
  • Epsom salts magnesium bromide, calcium chloride, calcium bromide, sodium bromide and magnesium sulfate
  • cromolyn which is a PAR-2 inhibitor. It is therefore an object of the invention to provide a method for the treatment of irritations and inflammations of the nasal passageways with an aqueous composition comprising magnesium and potassium chloride. It is another object of the invention to reduce the presence of allergen and irritants in the nasal passageways by irrigation with an aqueous composition comprising inert salts.
  • the present invention relates to a method of treating a patient suffering from an irritation and/or inflammations of the nasal passageway and cavity. More particularly, there is provided a method of nasally administering an effective amount of an aqueous composition comprising: A) About 1 to 10% by weight, preferably about 1 to 5% by weight of salts comprising: 1) About 45 to 60% of magnesium chloride, preferably about 55 to 58%.
  • the composition is preferably at a pH between 6.0 and 7.5.
  • the buffer can comprise a buffer selected from the groups comprising sodium phosphate, potassium phosphate, sodium carbonate and the like as is commonly used by those skilled in the art.
  • the composition can include other inorganic sales selected from the group consisting of magnesium bromide, potassium bromide, calcium chloride, magnesium sulfate, calcium bromide or a mixture thereof in amount of about 0.5 to 4%.
  • the aqueous composition may include cromolyn in an amount of about 0.5 to 4%, preferably 0.5 to 1%, to further inhibit the degranulation of mast cells and also inhibit the activation of arachadonic acid caused by irritants.
  • Zinc ions such as in the form of zinc gluconate, have been found useful when viruses are involved and can be used in amounts up to 2%.
  • Plant extract can be included such as echinacea which has been reported to inhibit gram-negative bacteria, Myrrh oil from cammphora abyssinica which helps to fight infection, and terpenes such as eucalyptus which is antiviral and aids in decongestion.
  • the plant extracts can be used in amounts of about 0.5 to 2% by weight.
  • a preferred 100 ml composition of the present invention comprises: Ingredient Wt. Magnesium Chloride 1.0 - 2.00g Magnesium Bromide 0.01 - 0.05 Magnesium Sulfate 0.01 - 0.05 Potassium Chloride 0.8 - 1 00g Calcium Chloride 0 - 0.05g Sodium Carbonate 0 - 0.05g 1% Saline Solution q.s. Optionally about O.lg of cromolyn may be added.
  • the pharmaceutical compositions may be prepared for nasal administration according to standard formulating procedures.
  • the salts may be dissolved in sterile water, physiological saline solution or buffer solution with a pH of 6.5 to 7.5 which is advantageously ironically balanced.
  • the preferred formulation for borax buffer is as follows: Solution A-1.9g Na 2 P 4 0 7 per 100 ml of H 2 0. Solution B-1.25 g H 3 B0 3 + 0.3 g NaCl per 100 ml H 2 0 is mixed with Solution A and the salts are added. It is preferred to include a preservative, for example, Thimerosal or benzalkonium chloride and/or an antioxidant, for example, vitamin E.
  • compositions are generally administered every four to eight hours and/or as conditions of the patient and atmosphere require.
  • the following examples further illustrate the practice of this invention, but are not intended to be limiting thereof. It will be appreciated that the selection of actual amounts of composition to be administered to any individual patient will fall within the discretion of the attending physician and will be prescribed in a manner commensurate with the appropriate dosages will depend on the stage of the disease and like factors uniquely within the purview of the attending physician.
  • Example 1 A composition which is effective as a nasal spray or nose drops is prepared as follows: Ingredient % Weight Magnesium Chloride 1.0 mg Potassium Chloride 1.0 mg 10% Saline Solution 97.9 Anti-oxidant 0.1 mg
  • composition may additionally include 0.5% of magnesium sulfate and 0.5% of magnesium bromide.
  • Example 2l solution which is effective as a nasal spray or nose drops is prepared as follows: Ingredient List
  • cromolyn may be added.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

There is provide a method of treating irritations and inflammation of the nasal passageways and cavity by the nasal administration of an aqueous composition containing magnesium, potassium and sodium halides.

Description

Method of Treatment
Field of the Invention The present invention relates to the treatment of irritations and inflammations of the nasal passageways and cavity. More particularly, there is provided an aqueous composition of inorganic salts that prevents the degranulation of mast cells, inhibits the release of arachadonic acid and 5-lipoxygenase enzyme and irrigates the nasal passageways. Background of the Invention Allergic rhinitis, sinusitis, and epistaxis, as well as common irritations, can each be induced by any one of smoke, chemicals, pollens, mold or dust mites. Pollens cause the release of serine proteases such as tryptase and chymase and the activation of IgE which causes the degranulation of mast cells so as to initiate the acute inflammatory cycle. Mast cells release histamines release factors. Through a number of mechanisms the results can be itchy nose, rhinorrhea and itchy and watery eyes. Inflammation by smoke or chemicals can cause the release of arachadonic acid as well as leukotriene B4. Dust mites are known to increase the amount of eosinophiles in asthma patients. Steroids such as triamcinolone acetonide have been commonly used to treat the symptoms. However, there are problems associated with prolonged use of steroids. More particularly, steroid use by children has been discouraged because nasal sprays will cause swallowing by children so that side effects may result. The use of anti-histamines does not solve the inflammation resulting from mast cell degranulation and cannot be used over prolonged periods. Trypsin which is released by mast cells triggers the release of proteinase activating factors (PARS) especially PAR-2 which has a role in inflammation and inducing arachadonic acid release. Cromolyn inhibits the activation of PAR-2 and aids in the prevention of the degranulation of mast cells. Since any different number of factors are involved in causing nasal irritations and inflammations, it would be preferable to have a method of treatment which can reduce the allergens or irritants in the nasal passageways that can be used over long periods of time as well as treat any inflammations that can be used by children as well as adults. Summary of the Invention There is provided an aqueous composition and method for treating the symptoms associated with the irritation and inflammation of nasal passages and nasal cavity caused by allergens and irritants which cause the degranulation of mast cells, release of arachadonic acid and serine proteases. More particular, there is provided a method of irrigating and treating the nasal passageways with an aqueous composition comprising a) About 1 to 10 percent by weight of salts comprising 1) About 45 to 60% of magnesium chloride, 2) About 29 to 41% of potassium chloride, and 3) About 1 to 4% of sodium chloride. b) The remainder being water. Preferably, the composition is buffered by a pH of about 6.0 to 7.5. The composition may include plant extracts especially for irrigation and as a decongestant. Advantageously, the composition contains about 1 to 5% by weight of salts selected from the group consisting of magnesium bromide, calcium chloride, calcium bromide, sodium bromide and magnesium sulfate (Epsom salts). It is further advantageous to include in the composition cromolyn, which is a PAR-2 inhibitor. It is therefore an object of the invention to provide a method for the treatment of irritations and inflammations of the nasal passageways with an aqueous composition comprising magnesium and potassium chloride. It is another object of the invention to reduce the presence of allergen and irritants in the nasal passageways by irrigation with an aqueous composition comprising inert salts. It is yet another object of the invention to prevent the degranulation of mast cells and to inhibit the release of arachadonic acid and histamine. Bacterial, viral and fungal inflammation also increase the problem. Description of the Preferred Embodiments The present invention relates to a method of treating a patient suffering from an irritation and/or inflammations of the nasal passageway and cavity. More particularly, there is provided a method of nasally administering an effective amount of an aqueous composition comprising: A) About 1 to 10% by weight, preferably about 1 to 5% by weight of salts comprising: 1) About 45 to 60% of magnesium chloride, preferably about 55 to 58%. 2) About 29 to 41% of potassium chloride, preferably about 39 to 40%, and 3) About 0 to 4% of sodium chloride, preferably about 1 to 2%, and B) The remainder water, whereby the irritation and/or inflammation is reduced. The composition is preferably at a pH between 6.0 and 7.5. The buffer can comprise a buffer selected from the groups comprising sodium phosphate, potassium phosphate, sodium carbonate and the like as is commonly used by those skilled in the art. The composition can include other inorganic sales selected from the group consisting of magnesium bromide, potassium bromide, calcium chloride, magnesium sulfate, calcium bromide or a mixture thereof in amount of about 0.5 to 4%. The aqueous composition may include cromolyn in an amount of about 0.5 to 4%, preferably 0.5 to 1%, to further inhibit the degranulation of mast cells and also inhibit the activation of arachadonic acid caused by irritants. Zinc ions, such as in the form of zinc gluconate, have been found useful when viruses are involved and can be used in amounts up to 2%. Plant extract can be included such as echinacea which has been reported to inhibit gram-negative bacteria, Myrrh oil from cammphora abyssinica which helps to fight infection, and terpenes such as eucalyptus which is antiviral and aids in decongestion. The plant extracts can be used in amounts of about 0.5 to 2% by weight. The zinc ions and the plant extracts are particularly useful in irrigating the nasal passageways to reduce the allergens or irritants and when a viral infection is suspected. A preferred 100 ml composition of the present invention comprises: Ingredient Wt. Magnesium Chloride 1.0 - 2.00g Magnesium Bromide 0.01 - 0.05 Magnesium Sulfate 0.01 - 0.05 Potassium Chloride 0.8 - 1 00g Calcium Chloride 0 - 0.05g Sodium Carbonate 0 - 0.05g 1% Saline Solution q.s. Optionally about O.lg of cromolyn may be added. The pharmaceutical compositions may be prepared for nasal administration according to standard formulating procedures. The salts may be dissolved in sterile water, physiological saline solution or buffer solution with a pH of 6.5 to 7.5 which is advantageously ironically balanced. For example, the preferred formulation for borax buffer is as follows: Solution A-1.9g Na2P407 per 100 ml of H20. Solution B-1.25 g H3B03 + 0.3 g NaCl per 100 ml H20 is mixed with Solution A and the salts are added. It is preferred to include a preservative, for example, Thimerosal or benzalkonium chloride and/or an antioxidant, for example, vitamin E. Other filler materials which can be included and are commonly found in nasal compositions include sodium carbonate solution, sorbitol solution, particularly potassium sorbate solution with a pH of 6-6.5, polyethylene glycol and the like. The compositions are generally administered every four to eight hours and/or as conditions of the patient and atmosphere require. The following examples further illustrate the practice of this invention, but are not intended to be limiting thereof. It will be appreciated that the selection of actual amounts of composition to be administered to any individual patient will fall within the discretion of the attending physician and will be prescribed in a manner commensurate with the appropriate dosages will depend on the stage of the disease and like factors uniquely within the purview of the attending physician.
Example 1 A composition which is effective as a nasal spray or nose drops is prepared as follows: Ingredient % Weight Magnesium Chloride 1.0 mg Potassium Chloride 1.0 mg 10% Saline Solution 97.9 Anti-oxidant 0.1 mg
The composition may additionally include 0.5% of magnesium sulfate and 0.5% of magnesium bromide. Example 2l solution which is effective as a nasal spray or nose drops is prepared as follows: Ingredient List
Magnesium Chloride 0.30 mg
Magnesium Bromide 0.05
Magnesium Sulfate 0.05
Potasium Chloride 0.3 mg
Potassium sorbate solution 10.0 mg
Vitamin E 0.01
Purified Water q.s.
Optionally, about 0.05 mg of cromolyn may be added.

Claims

What is Claimed:
1. A method of treating a patient suffering from inflammation or irritation of the nasal passageways characterized by nasally administering an effective amount of an aqueous composition comprising: A) about 1 to 10% by weight of salts comprising: 1) About 45 to 60% by weight of magnesium chloride; 2) About 29 to 40% by weight of potassium chloride, and 3) About 0 to 4% by weight of sodium chloride; and B) the remainder being water, whereby the irritation or inflammation is reduced.
2. The method of claim 1 characterized by the fact that said composition includes about 0.5 to 4% by weight of inorganic salts selected from the group consisting of magnesium bromide, potassium bromide, calcium chloride and magnesium sulfate.
3. The method of claims 1 or 2 characterized by the fact that said aqueous composition is buffered at pH 6.0 to 7.5.
4. The method of claim 1 characterized by the fact that said aqueous composition contains 0.5 to 4% cromolyn.
5. The method of claim 1 characterized by said composition having a plant extract selected from the group consisting of Echinacea, Myrrh oil, Eucalyptus and Aloe vera.
6. The method of claim 1 characterized by said composition containing zinc ions.
7. The method of claim 6 characterized by said zinc ion is from zinc gluconate.
8. The method of claim 1 characterized by a 100 ml of said aqueous composition comprising: Ingredient Wt. Magnesium Chloride 1.0 - 2. OOg Magnesium Bromide 0.01 - 0.05g Magnesium Sulfate 0.01 - 0.05g Potassium Chloride 0.08 - 1 OOg Calcium Chloride 0 - 0.05g Sodium Carbonate 0 - 0.05g 1% Saline Solution q.s.
9. A method for irrigating nasal passageways characterized by nasally administering the composition of claim 8.
10. The method of claim 9 characterized by said composition being buffered at pH 6.0 - 7.5.
11. A composition for treating inflammation and irritation of the nasal passageway characterized by: A) about 1 to 10% by weight of salts comprising: 1) about 45 to 60% by weight of magnesium chloride; 2) about 29 to 40% by weight of potassium chloride; 3) about 0 to 4% by weight of sodium chloride, and 4) about 0 to 4% by weight of cromolyn, and B) the remainder being water.
PCT/US2005/002775 2004-02-05 2005-02-01 Method of treatment WO2005077189A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77268804A 2004-02-05 2004-02-05
US10/772,688 2004-02-05

Publications (1)

Publication Number Publication Date
WO2005077189A1 true WO2005077189A1 (en) 2005-08-25

Family

ID=34080913

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/002775 WO2005077189A1 (en) 2004-02-05 2005-02-01 Method of treatment

Country Status (2)

Country Link
IL (1) IL160936A0 (en)
WO (1) WO2005077189A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014023720A1 (en) * 2012-08-10 2014-02-13 Laboratoire De La Mer Composition for washing or treating the nasal-sinus cavities
US9265749B2 (en) 2014-02-10 2016-02-23 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
EP3043650A4 (en) * 2013-09-10 2017-11-08 Kenneth P. Glynn Carbon dioxide and saline nasal delivery methods and delivery devices
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10265267B2 (en) 2016-08-31 2019-04-23 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US10561635B2 (en) 2016-10-07 2020-02-18 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
US10835512B2 (en) 2014-02-10 2020-11-17 Respivant Sciences Gmbh Methods of treating respiratory syncytial virus infections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466680A (en) * 1992-03-26 1995-11-14 Cytologics, Inc. Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
US6562363B1 (en) * 1997-09-26 2003-05-13 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6630163B1 (en) * 1999-04-22 2003-10-07 Howard Murad Method of treating dermatological disorders with fruit extracts

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466680A (en) * 1992-03-26 1995-11-14 Cytologics, Inc. Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
US6562363B1 (en) * 1997-09-26 2003-05-13 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6630163B1 (en) * 1999-04-22 2003-10-07 Howard Murad Method of treating dermatological disorders with fruit extracts

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2994389A1 (en) * 2012-08-10 2014-02-14 De La Mer Laboratoire COMPOSITION FOR THE WASHING OR TREATMENT OF NASO-SINUSIAN CAVITIES
WO2014023720A1 (en) * 2012-08-10 2014-02-13 Laboratoire De La Mer Composition for washing or treating the nasal-sinus cavities
EP3043650A4 (en) * 2013-09-10 2017-11-08 Kenneth P. Glynn Carbon dioxide and saline nasal delivery methods and delivery devices
US10238628B2 (en) 2014-02-10 2019-03-26 Respivant Sciences Gmbh Mast cell stabilizers treatment for systemic disorders
US9707206B2 (en) 2014-02-10 2017-07-18 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
US9962363B2 (en) 2014-02-10 2018-05-08 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
US9968586B2 (en) 2014-02-10 2018-05-15 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
US10835512B2 (en) 2014-02-10 2020-11-17 Respivant Sciences Gmbh Methods of treating respiratory syncytial virus infections
US9265749B2 (en) 2014-02-10 2016-02-23 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US10398673B2 (en) 2014-02-10 2019-09-03 Respivant Services GmbH Mast cell stabilizers treatment for systemic disorders
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US10391078B2 (en) 2015-08-07 2019-08-27 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10596146B2 (en) 2015-08-07 2020-03-24 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10265267B2 (en) 2016-08-31 2019-04-23 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
US10463613B2 (en) 2016-08-31 2019-11-05 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
US10561635B2 (en) 2016-10-07 2020-02-18 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
US10583113B2 (en) 2016-10-07 2020-03-10 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis

Also Published As

Publication number Publication date
IL160936A0 (en) 2004-08-31

Similar Documents

Publication Publication Date Title
WO2005077189A1 (en) Method of treatment
US5897872A (en) Iodine-containing nasal moisturizing saline solution
US10660914B2 (en) Stuffy nose deblocking composition having antiviral activity
KR100347651B1 (en) Antimicrobial treatment for herpes simplex virus and other infectious diseases
US7541052B1 (en) Hypertonic solutions and method of treatment
US6171611B1 (en) Iodine-containing nasal moisturizing saline and mouthwash solutions
US20090191288A1 (en) Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases
US9662360B2 (en) Treatment of herpes, pseudomonas, staph, and hepatitis
WO2016067283A1 (en) Virucidal compositions comprising tannins for nasal and pulmonary administration
WO2015082965A2 (en) Novel chitosan nasal wash
ES2482815T3 (en) Antibacterial compositions for the treatment of upper and lower respiratory tract infections
EP1283043B1 (en) Ophthalmic solution
CA3176035C (en) Antiviral & virucidal nasal spray compositions and related treatment methods
US20040116521A1 (en) Fungicidal agent containing n-chlorotaurine and use thereof
EP1803458A1 (en) Use of inorganic salts in the treatment of inflammation
US20240091153A1 (en) Composition for use as an antiviral in the form of nasal drops and in nebulisers
EP2604298A1 (en) Multipurpose solutions for contact lens care comprising chamomile
US20170326123A1 (en) Throat solution for treatment of cold, flu and sore throat
AU2023263539A1 (en) Compositions and uses therefor
US20170348260A1 (en) Nasal irrigation
WO2020142054A2 (en) Nasal spray formulation
CN110870847A (en) Eye drop capable of assisting in treating conjunctivitis
PL220390B1 (en) Preventive hygienic rinsing and nasal moisturizing agent
KR20170086848A (en) nasal cavity cleaner
CN101156871A (en) Ocean deep water nose drops

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase